Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

We continue to feel confident about our ability to capture 90%," LPL CEO Rich Steinmeier told analysts during the firm's 2nd ...

Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

William Blair is the premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to ...

William Blair is increasingly known for its prominence in the asset management business, with a global footprint of more than $81.9 billion¹ in client assets as of December 31, 2018.